Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;4(9):e582-e585.
doi: 10.1016/S2665-9913(22)00190-4. Epub 2022 Jul 12.

Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City

Amit Saxena  1 , Alexis J Engel  1 , Brittany Banbury  1 , Ghadeer Hasan  1 , Nicola Fraser  1 , Devyn Zaminski  1 , Mala Masson  1 , Rebecca H Haberman  1 , Jose U Scher  1 , Gary Ho  1 , Jammie Law  1 , Paula Rackoff  1 , Chung-E Tseng  1 , H Michael Belmont  1 , Robert M Clancy  1 , Jill P Buyon  1 , Peter M Izmirly  1
Affiliations

Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City

Amit Saxena et al. Lancet Rheumatol. 2022 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

AS, AJE, JPB, and PMI contributed equally to this work. AS, AJE, NF, RMC, JPB, and PMI conceived the study. AS, BB, GHa, and PMI performed the literature search. AS, AJE, BB, GHa, NF, DZ, MM, GHo, JL, PR, C-ET, HMB, RMC, JPB, and PMI performed data collection. AS, AJE, JPB, and PMI created the figures and wrote the original draft. All authors performed interpretation and analysis of data, reviewed or edited the manuscript, approved the final version for publication, and agree to be accountable for all aspects of the work. AS, AJE, and PMI verified the underlying data. AS, AJE, JPB, and PMI had final responsibility for the decision to submit for publication. AS has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, and Kezar Life Sciences. RHH has received consulting compensation from Janssen. JUS has served as a consultant for Janssen, Amgen, Pfizer, Sanofi, UCB, Bristol-Myers Squibb, and Abbvie; and has received funding for investigator-initiated studies from Pfizer and Janssen. RMC has received consulting fees from Momenta–Janssen. JPB has received consulting fees and served on data and safety monitoring boards for Momenta–Janssen, Ventus, Equillium, and GlaxoSmithKline. PMI has received consulting fees from GlaxoSmithKline and Momenta–Janssen. All other authors declare no competing interests. Deidentified participant data will be made available upon request by email to the corresponding author. This work was supported by the National Institutes of Health–National Institute of Arthritis and Musculoskeletal and Skin Diseases (P50 AR07059) to JPB and PMI and Bloomberg Philanthropies COVID-19 Response Initiative Grant to JUS and PMI. The funders of the study had no role in study design, data collection, data analysis, data interpretation, writing of the report, or decision to submit for publication.

Similar articles

See all similar articles

Cited by

References

    1. Fernandez-Ruiz R, Masson M, Kim MY, et al. Leveraging the United States epicenter to provide insights on COVID-19 in patients with systemic lupus erythematosus. Arthritis Rheumatol (Hoboken, NJ) 2020;72:1971–1980. - PMC - PubMed
    1. Ugarte-Gil MF, Alarcón GS, Izadi Z, et al. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Ann Rheum Dis. 2022;81:970–978. - PMC - PubMed
    1. Liew J, Gianfrancesco M, Harrison C, et al. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open. 2022;8 - PMC - PubMed
    1. Izmirly PM, Kim MY, Samanovic M, et al. Evaluation of immune response and disease status in SLE patients following SARS-CoV-2 vaccination. Arthritis Rheumatol. 2022;74:284–294. - PMC - PubMed
    1. Haberman RH, Um S, Axelrad JE, et al. Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease. Lancet Rheumatol. 2022;4:e384–e387. - PMC - PubMed

LinkOut - more resources